A clinical trial is a research study in which human volunteers receive a specific treatment or intervention so researchers can measure its effects on health. It is the primary way new drugs, vaccines, medical devices, and therapies are tested before they become available to the public. Every prescription medication on pharmacy shelves today passed through a series of clinical trials before earning approval.
How Clinical Trials Differ From Other Studies
The term “clinical trial” refers specifically to an interventional study, one where participants are assigned to receive a particular treatment (or no treatment) and then monitored for outcomes. This distinguishes it from an observational study, where researchers simply watch and record what happens to people without assigning them to any group. In a clinical trial, the researchers control who gets what. In an observational study, they don’t.
That distinction matters because assigning people to groups is what allows researchers to draw cause-and-effect conclusions. If a group receiving a new drug improves more than a group receiving a placebo, the trial’s design makes it possible to attribute that improvement to the drug itself rather than to chance, lifestyle differences, or the simple expectation of getting better.
Why Randomization and Blinding Matter
The most rigorous clinical trials are randomized, double-blind, and placebo-controlled. Each of those terms describes a specific safeguard against bias.
Randomization means participants are assigned to treatment or control groups by chance, not by a doctor’s choice or a patient’s preference. This prevents selection bias and balances out factors that could skew results, including ones researchers don’t even know about. If sicker patients ended up clustered in one group, for example, the results would be unreliable. Randomization makes that unlikely.
Blinding means that participants, and often the researchers themselves, don’t know who is receiving the real treatment and who is receiving the placebo. In a double-blind trial, neither side knows. This eliminates the possibility that expectations influence how symptoms are reported or how outcomes are measured. A patient who knows they’re on the experimental drug might unconsciously report feeling better. A researcher who knows which group a patient belongs to might unconsciously evaluate them differently.
The placebo, typically a sugar pill or saline injection that looks identical to the real treatment, serves as the baseline. Any improvement in the placebo group reflects the natural course of the disease plus the psychological effect of being treated. The experimental drug has to outperform that baseline to be considered effective.
The Four Phases of Testing
Clinical trials proceed through four distinct phases, each with a different goal and scale.
Phase 1 enrolls 20 to 100 volunteers, often healthy people, and lasts several months. The goal is basic safety: finding out what doses the human body can tolerate and identifying early side effects. This is the first time a treatment is tested in people.
Phase 2 expands to up to several hundred participants who have the disease or condition the treatment targets. These trials last several months to two years and focus on whether the treatment actually works while continuing to track side effects.
Phase 3 involves 300 to 3,000 participants and runs one to four years. This is the large-scale test of effectiveness. Researchers compare the new treatment against existing standard treatments or a placebo, looking for both benefits and adverse reactions across a much bigger and more diverse group. Phase 3 results are typically what the FDA reviews when deciding whether to approve a drug.
Phase 4 happens after a drug is already approved and on the market. These studies, sometimes involving thousands of people, monitor long-term safety and effectiveness in real-world conditions. Rare side effects that didn’t surface in earlier phases sometimes emerge here.
Most Drugs Don’t Make It
The path from Phase 1 to approval is steep. Only about 13.8% of drug development programs that enter Phase 1 eventually receive FDA approval. The biggest drop-off happens between Phase 2 and Phase 3: roughly half of drugs that complete Phase 2 never advance further, often because they don’t show enough effectiveness to justify the massive investment a Phase 3 trial requires. Of those that do reach Phase 3, about 59% ultimately win approval.
The financial stakes reflect that attrition. The average cost to develop a single new drug is roughly $173 million when counting only the successful program. But when factoring in the cost of all the failures along the way, plus the capital tied up over years of development, the expected cost rises to approximately $879 million per approved drug. The entire process, from preclinical lab work through FDA review, typically spans over a decade. Phase 3 alone averages about 38 months, and FDA review adds another 16.
Who Can Participate
Every trial has eligibility criteria that define who can and can’t enroll. Inclusion criteria specify what characteristics a participant must have, such as a particular disease stage, age range, or health marker. Exclusion criteria disqualify people whose other medical conditions or medications could interfere with the results or put them at unacceptable risk.
These filters exist for good reason: a more uniform study population makes it easier to detect whether a treatment works. But overly narrow criteria have drawn criticism for producing results that don’t reflect the broader population who will eventually use the drug. A treatment tested almost entirely in younger, healthier patients may behave differently in older adults with multiple health conditions. The FDA now requires sponsors of Phase 3 drug trials and certain device studies to submit a Diversity Action Plan before enrollment begins. These plans must set specific goals for enrollment broken down by race, ethnicity, sex, and age, along with an explanation of how those goals will be met.
How Participants Are Protected
Before any clinical trial can begin, the sponsor must submit an Investigational New Drug application to the FDA. The FDA then has 30 days to review the submission for safety before any participant receives the treatment. Separately, an Institutional Review Board, an independent committee that includes scientists, ethicists, and community members, must approve the trial’s design and has the authority to require changes or shut down a study entirely.
Every participant goes through a formal informed consent process before enrolling. This isn’t just signing a form. Federal regulations require that participants receive clear information about eight specific elements: what the study involves, the risks and discomforts, potential benefits, alternative treatments available outside the trial, how their privacy will be protected, what compensation or medical treatment is available if something goes wrong, who to contact with questions, and an explicit statement that participation is voluntary. The IRB oversees this process to make sure no one is pressured or misled into joining.
Benefits and Risks of Joining a Trial
People join clinical trials for a range of reasons. Some hope to access a promising new treatment before it’s widely available, particularly when existing options haven’t worked for them. Others want to contribute to research that could help future patients with the same condition. Participants also tend to receive closer medical monitoring than they would in routine care, and they often learn more about their own condition in the process.
The risks are real, though. The experimental treatment might not work, or it might cause side effects ranging from mild discomfort to serious complications. You might be assigned to the control group and receive a placebo instead of the active treatment, without knowing which group you’re in. Trials can also be time-consuming, requiring extra appointments, procedures, or hospital stays beyond what normal treatment would involve. And because the whole point of a trial is to test something whose full effects aren’t yet known, there’s an inherent element of uncertainty that doesn’t exist with established therapies.
How Trials Lead to Approved Treatments
When Phase 3 trials produce strong evidence that a treatment is safe and effective, the sponsor compiles the data into a New Drug Application and submits it to the FDA for review. The review process averages about 16 months. FDA reviewers examine the trial data, inspect manufacturing facilities, and evaluate proposed labeling before making a decision. If approved, the drug moves to market, though Phase 4 monitoring continues to track its performance in the wider population.
This system is far from perfect. It’s expensive, slow, and filters out treatments that might help some patients even if they don’t show a strong enough average effect across a whole trial population. But for all its limitations, the phased trial process remains the most reliable method available for determining whether a medical treatment does what it claims to do without causing unacceptable harm.